Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Journal Articles

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Takeshi Harada, MD PhD, Asuka Oda, PhD, Yohann Grondin, PhD, Jumpei Teramachi, DDS, PhD, Ariunzaya Bat-Erdene, MD PhD, Masami Iwasa, MD, Masahiro Oura, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Shiro Fujii, MD, Hirokazu Miki, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2018-99-114086

Published: 2018

Journal Articles

Expansion of γδT Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors

Hirokazu Miki, MD PhD, Takeshi Harada, MD PhD, Qu Cui, MD PhD, Asuka Oda, Ariunzaya Bat-Erdene, Hirofumi Tenshin, DDS, Ryota Amachi, DDS, PhD, Ryohei Sumitani, MD, Munenori Uemura, MD, Mamiko Takahashi, MD, Masami Iwasa, MD, Shiro Fujii, MD, Jumpei Teramachi, DDS, PhD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Masahiro Abe, MD PhD

Blood (2016) 128 (22): 2107.

https://doi.org/10.1182/blood.V128.22.2107.2107

Published: 2016

Journal Articles

Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma

Jumpei Teramachi, DDS, PhD, Masahiro Hiasa, PhD DDS, Asuka Oda, Hirofumi Tenshin, DDS, Ryota Amachi, DDS, PhD, Takeshi Harada, MDPhD, Derek Hanson, Keiichiro Watanabe, DDS, PhD, Shiro Fujii, MD, Kumiko Kagawa, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Itsuro Endo, MD PhD, Shuji Ozaki, MD PhD, Toshio Matsumoto, MD PhD, Masahiro Abe, MD PhD

Blood (2015) 126 (23): 4203.

https://doi.org/10.1182/blood.V126.23.4203.4203

Published: 2015

Journal Articles

The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib

Rebecca Silbermann, MD, Dan Zhou, Jumpei Teramachi, DDS, PhD, Xiang-Qun Xie, PhD, G. David Roodman, MD PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2014) 124 (21): 2083.

https://doi.org/10.1182/blood.V124.21.2083.2083

Published: 2014

Journal Articles

The Increased 1,25-(OH) 2 D 3 Sensitivity of Myeloma Cells and Marrow Stromal Cells Enhances RANKL Production and Tumor Cell Growth

Jumpei Teramachi, DDS, PhD, Noriyoshi Kurihara, DDS, PhD, John M Chirgwin, G David Roodman, MD, PhD

Blood (2012) 120 (21): 3946.

https://doi.org/10.1182/blood.V120.21.3946.3946

Published: 2012

Journal Articles

Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells

Jumpei Teramachi, DDS, PhD, Kyaw Ze Yar Myint, PhD, Rentian Feng, PhD, Xiangqun Xie, PhD, Jolene J. Windle, PhD, David Roodman, MD, PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2011) 118 (21): 888.

https://doi.org/10.1182/blood.V118.21.888.888

Published: 2011

Journal Articles

The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation

Jumpei Teramachi, DDS, PhD, Jolene J. Windle, PhD, David Roodman, MD, PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2010) 116 (21): 128.

https://doi.org/10.1182/blood.V116.21.128.128

Published: 2010

NARROW

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Expansion of γδT Cells By New Generation IMiDs and Their Cytotoxicity Against Myeloma Progenitors

Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma

The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib

The Increased 1,25-(OH) 2 D 3 Sensitivity of Myeloma Cells and Marrow Stromal Cells Enhances RANKL Production and Tumor Cell Growth

Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells

The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only